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Abstract
Objectives. It has been over 10 years since the first report of autoantibodies directed against phenylalanyl tRNA
synthetase (anti-Zo) in a patient with features of the anti-synthetase syndrome. In that time no further cases have
been published. Here we aim to characterize more fully the clinical phenotype of anti-Zo–associated myositis by
describing the clinical features of nine patients.
Methods. Anti-Zo was identified by protein-immunoprecipitation in patients referred for extended spectrum myo-
sitis autoantibody testing at our laboratory. Results were confirmed by immunodepletion using a reference serum.
Medical records were retrospectively reviewed to provide detailed information of the associated clinical phenotype
for all identified patients. Where possible, HLA genotype was imputed using Illumina protocols.
Results. Nine patients with anti-Zo were identified. The median age at disease onset was 51 years, and six
patients were female. Seven patients had evidence of inflammatory muscle disease, seven of interstitial lung dis-
ease and six of arthritis. The reported pattern of interstitial lung disease varied with usual interstitial pneumonia,
non-specific interstitial pneumonia and organizing pneumonia all described. Other features of the anti-synthetase
syndrome such as RP and mechanics hands were common. HLA data was available for three patients, all of
whom had at least one copy of the HLA 8.1 ancestral haplotype.
Conclusion. Patients with anti-Zo presenting with features of the anti-synthetase syndrome and interstitial lung
disease is a common finding. Like other myositis autoantibodies, there is likely to be a genetic association with the
HLA 8.1 ancestral haplotype.
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Introduction
The anti-synthetase syndrome is a well-described
clinical syndrome consisting of myositis, interstitial
lung disease (ILD), non-erosive arthritis, RP, fever, and
characteristic skin changes termed ‘mechanics’ hands’
[1]. Anti-synthetase syndrome is considered to be a
subgroup of the idiopathic inflammatory myopathies
(IIMs), although incomplete versions of the syndrome
are well recognized and not all patients have muscle
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. An association with the HLA8.1 ancestral haplotype is suggested.
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involvement. No formal definition or classification criteria
for anti-synthetase syndrome has been widely accepted,
but the development of EULAR-ACR Classification
Criteria for Antisynthetase Syndrome is an ongoing
initiative.
Patients with anti-synthetase syndrome have autoanti-
bodies directed against tRNA synthetases, a family of
cytoplasmic enzymes responsible for catalysing the
binding of amino acids to their corresponding tRNAs [1].
There are 20 different tRNA synthetases corresponding
to the 20 different amino acids, and thus far autoanti-
bodies targeting eight have been described in patients
with IIM. Anti-Jo-1, targeting histidyl tRNA synthetase, is
the most common autoantibody in adults with IIM and
can be identified in 15–30% of patients [1, 2]. The
remaining anti-tRNA synthetases; anti-PL7 (threonyl),
anti-PL12 (alanyl), anti-OJ (isoleucyl), anti-KS (aspar-
ginyl), anti-EJ (glycyl), anti-Zo (phenylalanyl) and anti-Ha
(tyrosyl) are rarer, collectively occurring in 10–20% of
cases [1, 2]. While anti-synthetase syndrome is generally
viewed as one syndrome, there are established differen-
ces between the clinical associations of the different
anti-synthetase autoantibodies [3–9]. While muscle dis-
ease is common in patients with anti-Jo1, anti-PL-7 or
anti-EJ, those with anti-PL-12, anti-KS or anti-OJ in con-
trast often have lung-dominant disease [9]. We were the
first to report autoantibodies directed against phenyla-
lanyl tRNA synthetase (anti-Zo) in a single patient with
myositis and now report on a series of nine patients
with this autoantibody [10].
Methods
Patients
Our laboratory has to date analysed >3000 serum sam-
ples by immunoprecipitation [2, 11]. Patients included in
this series were identified through autoantibody analysis
in our laboratory for research or diagnostic purposes.
Seven patients included were enrolled in the UKMyoNet
cohort. This cohort includes patients aged 18 years of
age or older who fulfill the Bohan and Peter criteria for
probable or definite PM/DM. A standardized clinical
data collection form, detailing demographics and indi-
vidual clinical details is used. Collaborating physicians at
each study site confirm the presence of ILD (by pulmon-
ary function testing and thoracic imaging) and cancer-
associated myositis (in the opinion of the recruiting
physician, by relevant investigations). Collection of blood
from patients was undertaken under the regulations of
the local research ethics committees [12, 13]. A further
two patients were identified through the diagnostic
screening service, samples having been sent for special-
ist, extended-spectrum autoantibody testing. These
patients were not required to meet any diagnostic
criteria.
Case notes were retrospectively reviewed for all
patients identified as anti-Zo–positive. There was no re-
quirement for patients to be screened by thoracic
imaging or pulmonary function testing, nor for formal
muscle strength testing or muscle biopsy to be per-
formed. All investigations were arranged by the treating
physician as deemed necessary. ILD was diagnosed by
the treating physician on the basis of investigations
arranged locally. Muscle involvement was similarly diag-
nosed on the basis of examination findings and local
investigations.
Written consent to participate and provide biological
samples was obtained from all subjects according to
the Declaration of Helsinki, and in compliance with local
ethics committee regulations.
Autoantibody identification
All samples were screened for the presence of autoanti-
bodies by radiolabelled protein immunoprecipitation as
described previously [10]. Where samples immunopreci-
pitated 58 kDa and 68 kDa bands, the presence of
anti-Zo was confirmed by immunodepletion using a ref-
erence serum (case 1, previously confirmed positive for
anti-Zo by mass spectrometry [10]).
For those patients participating in the UKMyonet co-
hort, samples were taken at the time of enrolment,
which may have been several years after disease onset.
For patients identified as having anti-Zo autoantibodies,
the samples analysed were taken up to 8 years post dis-
ease onset.
Indirect immunofluorescence
Indirect immunofluorescence was performed on HEp-2
cells (Nova-lite, Inova) according to the manufacturers’
instructions. All slides were read blindly and independ-
ently by two independent observers.
Evaluation of ENAs
The additional presence of antibodies targeting Ro52
and other ENAs was determined using line blot (ANA
profile 5, Euroimmun) according to the manufacturer’s
instructions.
HLA genotyping
Classical HLA alleles were imputed using SNP2HLA
from Immunochip genotyping data using a reference
panel generated by the Type 1 Diabetes Genetics
Consortium [14]. Genotyping was performed in accord-
ance with Illumina protocols at the Centre for
Musculoskeletal Research, University of Manchester,
UK. Standard quality control was performed as
described previously [15].
Results
Nine patients were identified as having 58 kDa and
68 kDa bands on immunoprecipitation, and all were sub-
sequently confirmed to have autoantibodies targeting
phenylalanyl tRNA synthetase by immunodepletion, (see
Fig. 1). All had a fine cytoplasmic speckled pattern on
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immunofluorescence, with titres ranging between 1:160
and 1:1280. Anti-Zo did not occur in conjunction with
any other myositis-specific autoantibody, but a number
of cases had additional autoantibodies targeting ENA, in
particular Ro52, see Table 1.
HLA data was available for three patients, all of whom
were Caucasian, and all of whom had at least one copy
of the ancestral haplotype DR3-DQ2.
Patients with anti-Zo autoantibodies had a median
age of disease onset of 51 years and a female to
male ratio of 6:3. All patients had many features of
the anti-synthetase syndrome, including inflammatory
arthritis, RP and mechanics’ hands. DM-associated
skin changes were present in three patients. Both
muscle involvement and ILD were common, each
occurring in seven (78%) of patients. Just over half of
the patients had both muscle and lung disease. The
pattern of ILD reported on high-resolution CT varied
and where identified ILD was present at diagnosis.
Patient nine had a history of endometrial carcinoma,
but no other patients had a history of concurrent ma-
lignancy. The clinical features of each patient are
summarized in Table 1.
Using the available data, the probability of IIM as the
diagnosis was calculated using the recently published
ACR/EULAR classification criteria calculator (http://www.
imm.ki.se/biostatistics/calculators/iim/) [16]. Results ranged
from 4–21% (patient 9) to 97–100% (patient 4). The
inclusion of anti-Jo1 as a surrogate for anti-Zo increased
the probability of IIM to ‘probable’ for patients 3 and 9
and to ‘definite’ for the remaining 7 patients. Probability
scores for all patients can be found in Table 1.
Data on treatment and outcome was limited. All
patients received steroids in addition to further im-
munosuppressive agents, as is standard clinical prac-
tice in the UK. Four patients received i.v. CYC
alongside prednisolone, and all responded well initially.
One patient required a second course of CYC following
a relapse 2 years later, and another patient relapsed
6 months later and subsequently received treatment
with rituximab. Patients were maintained on a number
of different immunosuppressive agents, including AZA,
MMF, CSA and tacrolimus. At the time of writing, one
patient had remained well off all treatment for 2 years.
Discussion
Anti-Zo is a rare anti-synthetase autoantibody, and this
case series is to date the largest cohort of such patients
described. All patients had a cytoplasmic speckle on in-
direct Hep2 cell immunofluorescence. The proportion of
females (66.7%) was similar to the 69.6% previously
reported for European patients with IIM [2]. Similarly, the
median age at onset of 50 years was similar to the
51 years previously reported for European patients with
FIG. 1 Immunodepletion experiments using prototype serum confirmed the presence of anti-Zo in all samples studied
Autoradiographs of 9% SDS–PAGE of immunoprecipitates from cases 1–8 serum, normal control serum or PL12/PL7
positive control sera immunoprecipitated using either control [35S] methionine-labelled cell extract (–), or [35S] methio-
nine-labelled cell extract depleted with either normal sera (NS) or case 1 sera (anti-phenylalanyl tRNA synthetase pre-
viously confirmed using mass spectrometry [10]). The bands corresponding to phenylalanyl tRNA synthetase alpha
(55 kDa) and phenylalanyl tRNA synthetase alpha (65 kDa) are indicated.
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IIM, although we note that six of the nine patients were
aged 51 years or less [2]. The frequency of different
myositis-related autoantibodies is known to vary de-
pending on age at disease onset, and it is possible that
anti-Zo is more common in younger adults. While IIM
can be associated with malignancy, the anti-synthetase
syndrome is not generally believed to carry a significant
increased risk of associated malignancy [2]. The only
patient with malignancy in this series was aged 79 years
old, and no clear link with anti-Zo is proposed.
ILD is a major cause of mortality in myositis and
occurs in up to 90% of adults with anti-synthetase syn-
drome [17, 18]. Patients with non-Jo-1 anti-synthetase
autoantibodies have been found to have a worse sur-
vival than those with anti-Jo-1 [3]. This may reflect that
these patients are more likely to present with incomplete
anti-synthetase syndrome, without muscle involvement,
in addition to challenges in autoantibody identification
and diagnosis. Only two patients with anti-Zo were clas-
sified as probable or definite IIM using the recently
ACR/EULAR Classification Criteria for Idiopathic
Inflammatory Myopathies [16]. ILD was common in
patients with anti-Zo: Seven (78%) of patients were
identified as having ILD, although the pattern of ILD
reported on high-resolution CT varied. It should be
noted that the reporting of HRCTs was not standardized
and is presented as was reported by the reporting radi-
ologist at each patient’s base hospital.
It is noteworthy that the sera from two-thirds of our
patients with anti-Zo also contained autoantibodies tar-
geting anti-Ro52. Anti-Ro52 has been previously shown
to occur commonly alongside other anti-synthetase
autoantibodies and has been associated with more se-
vere ILD [19, 20].
HLA variants on chromosome 6 have been established
as the strongest genetic risk factors for the development
of myositis [15]. Associations with certain HLA alleles
have been reported for various myositis-specific autoanti-
bodies, and the most well established is between anti-
Jo-1 and the ancestral haplotype containing HLA-
DRB1*03:01 [21]. Although data was limited and available
from just three patients in this series, it is noteworthy that
all contained at least one copy of the HLA 8.1 ancestral
haplotype, which includes HLA-DRB1*03:01. Further
work is needed, but as for other myositis-specific autoan-
tibodies, patients with anti-Zo are likely to have inde-
pendent associations with the HLA 8.1 ancestral
haplotype, which may relate to peptide-binding affinity.
All but two patients in this series had evidence of
muscle involvement, but given that all patients were
referred for myositis autoantibody testing and seven
were enrolled in the UKMyonet cohort and fulfilled
Bohan and Peter diagnostic criteria, the high propor-
tion of muscle disease is perhaps not surprising.
Some anti-synthetase autoantibody phenotypes are
associated with ‘lung-dominant’ disease’, and anti-
synthetase autoantibodies have been reported in
patients diagnosed with idiopathic ILD. Patients with
anti-Zo–associated anti-synthetase syndrome do not
all have evidence of muscle involvement, and this
should be considered in patients presenting with ILD
and/or with other features of the anti-synthetase syn-
drome, such as arthritis and RP, particularly when a
cytoplasmic speckle is seen on indirect Hep2 cell
immunofluorescence.
In conclusion, patients with anti-Zo autoantibodies
present with features of the anti-synthetase syndrome.
Most patients have myositis and ILD. Where anti-Zo
autoantibody testing is not available, a cytoplasmic
speckle on indirect immunofluorescence of Hep2 cells
and the presence of anti-Ro52 could provide useful
clues. As with other myositis-specific autoantibodies,
there is likely to be an association with the HLA 8.1 an-
cestral haplotype.
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